DUBLIN, September 23, 2022 /PRNewswire/ — The “Global Markets for Insulin Drug Technologies and Delivery” report has been added to the ResearchAndMarkets.com special offer.
The current report will provide an in-depth look at the market for insulin delivery drugs and technologies. This report analyzes the market trends of insulin delivery drugs and technologies with data from 2021, estimates from 2022, forecasts for annual growth rates to 2027 (forecast period 2022-2027) and the regional markets for drugs and insulin delivery technologies insulin administration.
This report will highlight the current and future potential of the insulin delivery drugs and technologies market along with a detailed analysis of the competitive landscape. Regulatory scenarios, drivers, constraints and opportunities will be covered in the current report. The report also covers market forecast to 2026 and market share for key market players.
Insulin drug and delivery technologies are used to manage type 1 and type 2 diabetes. Easy-to-use insulin delivery devices, such as smart pens, help diabetes patients optimize blood glucose control and minimize the risk of related health problems . Advanced insulin delivery devices offer better patient compliance.
Traditional insulin syringes and pumps are being replaced by reusable and disposable insulin pens due to the latter’s portability, greater dosing accuracy, built-in memory, larger doses, and ease of use. There was no breakthrough in traditional syringes and pumps.
Major manufacturers of insulin delivery devices include Medtronic, F. Hoffmann-La Roche (Roche) Ltd., Becton Dickinson (BD), Ypsomed AG and B. Braun Melsungen AG. Key manufacturers of modern insulin and human insulin include Sanofi, Eli Lilly, Novo Nordisk, Boehringer Ingelheim International GmbH, Biocon and Viatris Inc.
The growth of the market is attributed to factors such as increasing incidence of diabetes and new drug and insulin delivery technologies. The global insulin delivery drugs and technologies market is segmented by device type, insulin type, and region.
In this report, the market has been segmented on the basis of device type, insulin type, and geographical region. Device types include syringes, insulin pens, insulin pumps, smart pens, and more. Types of insulin include long-acting, rapid-acting, premixed, intermediate, and short-acting insulins.
Geographical areas covered include; North America, Europe, Asia-Pacific and the rest of the world (RoW). Individual countries covered include the US, Germanythe UK, Italy, France, Japan, China and India.
Descriptive company profiles of key manufacturers of modern insulin and insulin delivery devices, including Sanofi, Eli Lilly, Novo Nordisk, Medtronic, F. Hoffmann-La Roche (Roche) Ltd., Becton Dickinson (BD), Ypsomed AG and B. Braun Melsungen AG
The report includes
24 data tables and 31 additional tables
An updated review of global markets for drug and insulin delivery technologies
Global market trends analysis, with historical market revenue (sales figures) for 2020 and 2021, estimates for 2022 and forecast compound annual growth rates (CAGR) to 2027
Highlights of current status of Drug Delivery and Insulin Delivery industry structure, new technological updates and issues related to Insulin Pens and Syringes, current research activities and regulatory and pricing scenarios
Estimation of the actual market size and market forecast for drug delivery and insulin delivery technologies and analysis of the respective market share by device type, insulin type and geographic region
Up-to-date information on key M&A agreements, collaborations, partnerships and other strategic alliances in the pharmaceutical and insulin delivery technologies industry
Market opportunity analysis with a holistic review of Porter’s Five Forces analysis model, taking into account both the micro and macro environmental factors prevailing in the market
Identify key stakeholders and analyze the competitive landscape based on recent developments and sector-wise revenue
Key topics covered:
chapter 1 Introduction
1.1 Overview of insulin
1.2 Overview of diabetes
1.2.1 Disease symptoms and risk factors
1.2.2 Epidemiology and Economic Burden
1.3 Study Aims and Objectives
1.4 Reasons for doing this study
1.5 What’s new in this update?
1.6 Scope of the Report
1.7 Sources of Information
1.9 Geographical Analysis
1.10 Analyst Credentials
1.11 Custom Research
1.12 Related Research Reports
Chapter 2 Summary and Main Points
Chapter 3 Market Dynamics
3.1 Purchase Drivers
3.1.1 Increasing prevalence of diabetes
3.1.2 Smart Insulin Drug Delivery Technologies
3.1.3 Painless technologies for administering insulin drugs
3.2 Purchase Restrictions
3.2.1 Product recalls
3.3 Purchase Opportunities
3.3.1 Inorganic strategies among market players
Chapter 4 Market overview
4.1 Purchase Information
4.2 Current market trends
4.2.1 Recent Product Introductions
4.2.2 Recent Strategic Alliances
4.3 Future Outlook
Chapter 5 Regulatory landscape and compensation scenario
5.1 Regulatory Landscape
5.1.1 US Medical Device Regulations
5.1.2 US Drug Regulations
5.1.3 European Regulation for Medical Devices
5.1.4 European Drug Regulation
5.1.5 Asia Pacific Medical Device Regulations
5.2 Compensation Scenario
5.2.1 Pricing and Compensation Overview
5.2.2 Pricing and reimbursement for medical devices
5.2.3 Pricing and reimbursement for pharmaceutical products
5.3.1 Insurance for diabetes emergencies
Chapter 6 The impact of Covid-19 on the market
6.2 Covid-19 Crisis
6.2.1 Market implications for insulin drugs and delivery technologies
6.2.2 Covid-19 Measures
Chapter 7 Market Analysis by Device Type
7.1 Insulin delivery technologies
7.1.2 Insulin pens
7.1.3 Insulin pumps
7.1.4 Smart Pens
Chapter 8 Market Analysis by Type of Insulin
8.1.1 Structure of insulin
8.1.2 Biosynthesis of insulin
8.1.3 Types of insulin
Chapter 9 Market Analysis by Regions
9.1.1 North America
9.1.4 Rest of the World
Chapter 10 Market Opportunity Analysis
10.1 Porter’s five forces analysis
10.1.1 Threat of New Entrants
10.1.2 Threat of Substitutes
10.1.3 Bargaining Power of Suppliers
10.1.4 Bargaining Power of Buyers
10.1.5 Degree of Competition
Chapter 11 Competitive landscape
Chapter 12 Company Profiles
12.1 Large Companies
B. Braun Melsungen AG
Becton, Dickinson and Co.
Boehringer Ingelheim International GmbH
Eli Lilly and Co.
F. Hoffmann-La Roche Ltd.
Novo Nordisk A/S
Ypsomed Holding AG
Emperra GmbH E-Health Technologies
Nanopass Technologies Ltd.
Nipro Medical Corp.
Owen Mumford Ltd.
Tandem Diabetes Care Inc.
For more information on this report, visit https://www.researchandmarkets.com/r/qw0qyx
Research and Shopping
Laura WoodSenior Manager
For EST office hours call +1-917-300-0470
For US/CAN Call Toll Free +1-800-526-8630
For GMT office hours call +353-1-416-8900
US Fax: 646-607-1907
Fax (outside USA): +353-1-481-1716
See original content: https://www.prnewswire.com/news-releases/global-insulin-drug-and-delivery-technology-market-analysis-report-2022-rising-prevalence-of-diabetes-smart-insulin – drug-delivery-technologies–painless-insulin-drug-delivery-technologies-301631950.html
SOURCE Research and Markets